β2-Adrenergic receptor-dependent attenuation of hypoxic pulmonary vasoconstriction prevents progression of pulmonary arterial hypertension in intermittent hypoxic rats.

In sleep apnea syndrome (SAS), intermittent hypoxia (IH) induces repeated episodes of hypoxic pulmonary vasoconstriction (HPV) during sleep, which presumably contribute to pulmonary arterial hypertension (PAH). However, the prevalence of PAH was low and severity is mostly mild in SAS patients, and m...

Full description

Bibliographic Details
Main Authors: Hisashi Nagai, Ichiro Kuwahira, Daryl O Schwenke, Hirotsugu Tsuchimochi, Akina Nara, Tadakatsu Inagaki, Sayoko Ogura, Yutaka Fujii, Keiji Umetani, Tatsuo Shimosawa, Ken-ichi Yoshida, James T Pearson, Koichi Uemura, Mikiyasu Shirai
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4211686?pdf=render
id doaj-ff51a80565334b769eefcb4665705784
record_format Article
spelling doaj-ff51a80565334b769eefcb46657057842020-11-25T01:44:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01910e11069310.1371/journal.pone.0110693β2-Adrenergic receptor-dependent attenuation of hypoxic pulmonary vasoconstriction prevents progression of pulmonary arterial hypertension in intermittent hypoxic rats.Hisashi NagaiIchiro KuwahiraDaryl O SchwenkeHirotsugu TsuchimochiAkina NaraTadakatsu InagakiSayoko OguraYutaka FujiiKeiji UmetaniTatsuo ShimosawaKen-ichi YoshidaJames T PearsonKoichi UemuraMikiyasu ShiraiIn sleep apnea syndrome (SAS), intermittent hypoxia (IH) induces repeated episodes of hypoxic pulmonary vasoconstriction (HPV) during sleep, which presumably contribute to pulmonary arterial hypertension (PAH). However, the prevalence of PAH was low and severity is mostly mild in SAS patients, and mild or no right ventricular hypertrophy (RVH) was reported in IH-exposed animals. The question then arises as to why PAH is not a universal finding in SAS if repeated hypoxia of sufficient duration causes cycling HPV. In the present study, rats underwent IH at a rate of 3 min cycles of 4-21% O2 for 8 h/d for 6 w. Assessment of diameter changes in small pulmonary arteries in response to acute hypoxia and drugs were performed using synchrotron radiation microangiography on anesthetized rats. In IH-rats, neither PAH nor RVH was observed and HPV was strongly reversed. Nadolol (a hydrophilic β(1, 2)-blocker) augmented the attenuated HPV to almost the same level as that in N-rats, but atenolol (a hydrophilic β1-blocker) had no effect on the HPV in IH. These β-blockers had almost no effect on the HPV in N-rats. Chronic administration of nadolol during 6 weeks of IH exposure induced PAH and RVH in IH-rats, but did not in N-rats. Meanwhile, atenolol had no effect on morphometric and hemodynamic changes in N and IH-rats. Protein expression of the β1-adrenergic receptor (AR) was down-regulated while that of β2AR was preserved in pulmonary arteries of IH-rats. Phosphorylation of p85 (chief component of phosphoinositide 3-kinase (PI3K)), protein kinase B (Akt), and endothelial nitric oxide synthase (eNOS) were abrogated by chronic administration of nadolol in the lung tissue of IH-rats. We conclude that IH-derived activation of β2AR in the pulmonary arteries attenuates the HPV, thereby preventing progression of IH-induced PAH. This protective effect may depend on the β2AR-Gi mediated PI3K/Akt/eNOS signaling pathway.http://europepmc.org/articles/PMC4211686?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Hisashi Nagai
Ichiro Kuwahira
Daryl O Schwenke
Hirotsugu Tsuchimochi
Akina Nara
Tadakatsu Inagaki
Sayoko Ogura
Yutaka Fujii
Keiji Umetani
Tatsuo Shimosawa
Ken-ichi Yoshida
James T Pearson
Koichi Uemura
Mikiyasu Shirai
spellingShingle Hisashi Nagai
Ichiro Kuwahira
Daryl O Schwenke
Hirotsugu Tsuchimochi
Akina Nara
Tadakatsu Inagaki
Sayoko Ogura
Yutaka Fujii
Keiji Umetani
Tatsuo Shimosawa
Ken-ichi Yoshida
James T Pearson
Koichi Uemura
Mikiyasu Shirai
β2-Adrenergic receptor-dependent attenuation of hypoxic pulmonary vasoconstriction prevents progression of pulmonary arterial hypertension in intermittent hypoxic rats.
PLoS ONE
author_facet Hisashi Nagai
Ichiro Kuwahira
Daryl O Schwenke
Hirotsugu Tsuchimochi
Akina Nara
Tadakatsu Inagaki
Sayoko Ogura
Yutaka Fujii
Keiji Umetani
Tatsuo Shimosawa
Ken-ichi Yoshida
James T Pearson
Koichi Uemura
Mikiyasu Shirai
author_sort Hisashi Nagai
title β2-Adrenergic receptor-dependent attenuation of hypoxic pulmonary vasoconstriction prevents progression of pulmonary arterial hypertension in intermittent hypoxic rats.
title_short β2-Adrenergic receptor-dependent attenuation of hypoxic pulmonary vasoconstriction prevents progression of pulmonary arterial hypertension in intermittent hypoxic rats.
title_full β2-Adrenergic receptor-dependent attenuation of hypoxic pulmonary vasoconstriction prevents progression of pulmonary arterial hypertension in intermittent hypoxic rats.
title_fullStr β2-Adrenergic receptor-dependent attenuation of hypoxic pulmonary vasoconstriction prevents progression of pulmonary arterial hypertension in intermittent hypoxic rats.
title_full_unstemmed β2-Adrenergic receptor-dependent attenuation of hypoxic pulmonary vasoconstriction prevents progression of pulmonary arterial hypertension in intermittent hypoxic rats.
title_sort β2-adrenergic receptor-dependent attenuation of hypoxic pulmonary vasoconstriction prevents progression of pulmonary arterial hypertension in intermittent hypoxic rats.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description In sleep apnea syndrome (SAS), intermittent hypoxia (IH) induces repeated episodes of hypoxic pulmonary vasoconstriction (HPV) during sleep, which presumably contribute to pulmonary arterial hypertension (PAH). However, the prevalence of PAH was low and severity is mostly mild in SAS patients, and mild or no right ventricular hypertrophy (RVH) was reported in IH-exposed animals. The question then arises as to why PAH is not a universal finding in SAS if repeated hypoxia of sufficient duration causes cycling HPV. In the present study, rats underwent IH at a rate of 3 min cycles of 4-21% O2 for 8 h/d for 6 w. Assessment of diameter changes in small pulmonary arteries in response to acute hypoxia and drugs were performed using synchrotron radiation microangiography on anesthetized rats. In IH-rats, neither PAH nor RVH was observed and HPV was strongly reversed. Nadolol (a hydrophilic β(1, 2)-blocker) augmented the attenuated HPV to almost the same level as that in N-rats, but atenolol (a hydrophilic β1-blocker) had no effect on the HPV in IH. These β-blockers had almost no effect on the HPV in N-rats. Chronic administration of nadolol during 6 weeks of IH exposure induced PAH and RVH in IH-rats, but did not in N-rats. Meanwhile, atenolol had no effect on morphometric and hemodynamic changes in N and IH-rats. Protein expression of the β1-adrenergic receptor (AR) was down-regulated while that of β2AR was preserved in pulmonary arteries of IH-rats. Phosphorylation of p85 (chief component of phosphoinositide 3-kinase (PI3K)), protein kinase B (Akt), and endothelial nitric oxide synthase (eNOS) were abrogated by chronic administration of nadolol in the lung tissue of IH-rats. We conclude that IH-derived activation of β2AR in the pulmonary arteries attenuates the HPV, thereby preventing progression of IH-induced PAH. This protective effect may depend on the β2AR-Gi mediated PI3K/Akt/eNOS signaling pathway.
url http://europepmc.org/articles/PMC4211686?pdf=render
work_keys_str_mv AT hisashinagai b2adrenergicreceptordependentattenuationofhypoxicpulmonaryvasoconstrictionpreventsprogressionofpulmonaryarterialhypertensioninintermittenthypoxicrats
AT ichirokuwahira b2adrenergicreceptordependentattenuationofhypoxicpulmonaryvasoconstrictionpreventsprogressionofpulmonaryarterialhypertensioninintermittenthypoxicrats
AT daryloschwenke b2adrenergicreceptordependentattenuationofhypoxicpulmonaryvasoconstrictionpreventsprogressionofpulmonaryarterialhypertensioninintermittenthypoxicrats
AT hirotsugutsuchimochi b2adrenergicreceptordependentattenuationofhypoxicpulmonaryvasoconstrictionpreventsprogressionofpulmonaryarterialhypertensioninintermittenthypoxicrats
AT akinanara b2adrenergicreceptordependentattenuationofhypoxicpulmonaryvasoconstrictionpreventsprogressionofpulmonaryarterialhypertensioninintermittenthypoxicrats
AT tadakatsuinagaki b2adrenergicreceptordependentattenuationofhypoxicpulmonaryvasoconstrictionpreventsprogressionofpulmonaryarterialhypertensioninintermittenthypoxicrats
AT sayokoogura b2adrenergicreceptordependentattenuationofhypoxicpulmonaryvasoconstrictionpreventsprogressionofpulmonaryarterialhypertensioninintermittenthypoxicrats
AT yutakafujii b2adrenergicreceptordependentattenuationofhypoxicpulmonaryvasoconstrictionpreventsprogressionofpulmonaryarterialhypertensioninintermittenthypoxicrats
AT keijiumetani b2adrenergicreceptordependentattenuationofhypoxicpulmonaryvasoconstrictionpreventsprogressionofpulmonaryarterialhypertensioninintermittenthypoxicrats
AT tatsuoshimosawa b2adrenergicreceptordependentattenuationofhypoxicpulmonaryvasoconstrictionpreventsprogressionofpulmonaryarterialhypertensioninintermittenthypoxicrats
AT kenichiyoshida b2adrenergicreceptordependentattenuationofhypoxicpulmonaryvasoconstrictionpreventsprogressionofpulmonaryarterialhypertensioninintermittenthypoxicrats
AT jamestpearson b2adrenergicreceptordependentattenuationofhypoxicpulmonaryvasoconstrictionpreventsprogressionofpulmonaryarterialhypertensioninintermittenthypoxicrats
AT koichiuemura b2adrenergicreceptordependentattenuationofhypoxicpulmonaryvasoconstrictionpreventsprogressionofpulmonaryarterialhypertensioninintermittenthypoxicrats
AT mikiyasushirai b2adrenergicreceptordependentattenuationofhypoxicpulmonaryvasoconstrictionpreventsprogressionofpulmonaryarterialhypertensioninintermittenthypoxicrats
_version_ 1725027202960982016